Search results
Results from the WOW.Com Content Network
As of 2018, IDSA had more than 11,000 members from across the United States and nearly 100 other countries on six different continents. [2] IDSA's purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.
It is the most common bacterial pneumonia found in adults, the most common type of community-acquired pneumonia, and one of the common types of pneumococcal infection. The estimated number of Americans with pneumococcal pneumonia is 900,000 annually, with almost 400,000 cases hospitalized and fatalities accounting for 5-7% of these cases. [2]
The pneumonia severity index (PSI) or PORT Score is a clinical prediction rule that medical practitioners can use to calculate the probability of morbidity and mortality among patients with community acquired pneumonia. [1] The PSI/PORT score is often used to predict the need for hospitalization in people with pneumonia. [2]
An Ohio county is experiencing a pediatric outbreak of pneumonia, including a number of cases of mycoplasma pneumonia, the illness that has driven recent outbreaks among children in Denmark and China.
Pope Francis’ condition is “slightly improving” and he continues to have no fever, the Vatican said on Thursday evening, adding that he carried out work activities after receiving Eucharist ...
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person outside of the healthcare system. In contrast, hospital-acquired pneumonia (HAP) is seen in patients who have recently visited a hospital or who live in long-term care facilities.
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus. [1] [2]
The FDA said the drug was “nonapprovable”, but did not refer to specific safety concerns about the product. The company will have to conduct new studies and clinical trials, lasting an estimated two more years, to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections. [citation needed]